Virologist, Former Head of the Emerging and Vector borne Diseases programme, Office of the Chief Scientist, European Centre for Disease prevention and Control (ECDC) in Stockholm, Sweden, up to November 2017 with special focus on risk assessment in the European Union and neighbouring countries. Former director of the French National Reference Centres and World Health Organization (WHO) Collaborative Centre on Arboviruses and Viral Haemorrhagic Fevers in Pasteur Institute Paris/Lyon in France for 10 years (1998-2008).
Previous work for more than 20 years within the International Pasteur Institute network in several countries in Africa and the Americas, mostly on diagnostic and eco-epidemiological studies of viral diseases. Participation to several field response missions to emerging diseases outbreaks through the WHO Global Outbreak response network (GOARN) in Africa and Europe (Ebola/Marburg, yellow fever, Crimean-Congo haemorrhagic fever) as well as for ECDC within the European Union (dengue, West Nile).
Member of the WHO scientific and technical advisory group on yellow fever risk mapping (GRYF) and International h Regulation expert in Rift Valley fever.
In the last ten years, a network of medical and veterinarian entomologists (VectorNet/former VBorNet) has been established in the European region for mapping the main vectors of diseases of importance for humans and animals and providing expert support for assessing the risks. The diagnostic capacity for early detection and confirmation by reference laboratories of viral diseases has been strengthened through networking in Europe and surrounding countries (EVD-LabNet)/former ENIVD).
Wild life is involved in the transmission cycle of several vector-borne diseases in Europe. Knowing better the cycles of maintenance and propagation of these diseases in wildlife is a requirement to assess the risks for humans. A few examples will be presented to demonstrate the needs of a global approach involving multidisciplinary expertise to understand the mode of transmission of these diseases for risk mitigation and applying optimal control measures.